| Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID |
Health Care |
$14 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
23 Jul 2025 8:42AM |
$0.655 |
$0.110 |
fallen by
83.21%
|
|
AGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 2 clinical trial of ARG-007 commenced, enrolling first patients for acute ischaemic stroke treatment
- Successful site activations and regulatory approvals obtained for the trial
- ARG-007 positioned as a first-in-class neuroprotective drug with potential to improve stroke outcomes
- Ongoing collaborations with clinical and academic partners to support program advancement
- Corporate development activities include investor engagement and preparation for future milestones
- Operating cash outflows for the quarter were reported, with sufficient cash reserves to fund ongoing operations
- Appendix 4C provides detailed cash flow statements and commentary on expected future expenditures
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paladin Energy Ltd (PDN) ORDINARY FULLY PAID |
Energy |
$4,219 |
Quarterly Cashflow Report - June 2025
|
23 Jul 2025 8:42AM |
$8.170 |
$9.390 |
risen by
14.93%
|
|
PDN - Price-sensitive ASX Announcement
Full Release
Key Points
- Paladin Energy Ltd's cash flow report for the quarter ended 30 June 2025 was released.
- Net cash used in operating activities was USD 18.441 million for the current quarter.
- Cash flows from investing activities resulted in an outflow of USD 5.832 million.
- Cash flows from financing activities resulted in an outflow of USD 6.750 million.
- The company began with USD 117.331 million in cash and cash equivalents and ended with USD 89.048 million.
- Payments for the Langer Heinrich Restart Project amounted to USD 438,000 for the quarter.
- Paladin Energy completed acquisitions, including the acquisition of Fission Uranium Corp.
- Loan facilities include a USD 100 million amortising term loan and a USD 50 million revolving credit facility.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Paladin Energy Ltd (PDN) ORDINARY FULLY PAID |
Energy |
$4,219 |
Quarterly Cashflow Report - June 2025
|
23 Jul 2025 8:42AM |
$8.170 |
$9.390 |
risen by
14.93%
|
|
PDN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net decrease in cash and cash equivalents of USD 28.3 million.
- Operating activities saw a net cash outflow of USD 18.4 million.
- Investing activities resulted in a cash outflow of USD 5.8 million.
- Financing activities experienced a net outflow of USD 6.75 million.
- Cash and cash equivalents at the end of the period were USD 89.05 million.
- Total available funding amounted to USD 139.1 million.
- Unused finance facilities totaled USD 50.1 million.
- Details of payments to related parties, including directors' fees.
- Description of financing facilities and obligations with CNOL and external lenders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$33 |
AVM hits 100m AgEq - Guadalupe Y Calvo Acquisition
|
23 Jul 2025 8:42AM |
$0.043 |
$0.069 |
risen by
60.47%
|
|
| Rey Resources Limited (REY) ORDINARY FULLY PAID |
Energy |
- |
Notice of change of interests of substantial holder
|
23 Jul 2025 8:41AM |
$0.030 |
$0.027 |
fallen by
10%
|
|
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$597 |
Update - Notification of buy-back - FPR
|
23 Jul 2025 8:41AM |
$3.110 |
$2.770 |
fallen by
10.93%
|
|
| AuKing Mining Limited (AKN) ORDINARY FULLY PAID |
Materials |
$47 |
Noosa Mining Conference Presentation
|
23 Jul 2025 8:41AM |
$0.006 |
$0.022 |
risen by
266.67%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$4,941 |
Pending Release of Shares from Voluntary Escrow
|
23 Jul 2025 8:40AM |
$25.120 |
$14.560 |
fallen by
42.04%
|
|
| Qmines Limited (QML) ORDINARY FULLY PAID |
Materials |
$40 |
Noosa Mining Conference Presentation
|
23 Jul 2025 8:39AM |
$0.052 |
$0.052 |
fallen by
0%
|
|
| QPM Energy Limited (QPM) ORDINARY FULLY PAID |
Materials |
$71 |
SPP Results
|
23 Jul 2025 8:36AM |
$0.037 |
$0.018 |
fallen by
51.35%
|
|
QPM - Price-sensitive ASX Announcement
Full Release
Key Points
- QPM Energy Limited announced the results of its Small Producer Participation (SPP) offer.
- The SPP offer raised a total of $1,000,000 from eligible shareholders.
- A total of 20,000,000 new shares will be issued at the offer price.
- The shares were offered to eligible shareholders at a set price per share.
- The SPP was oversubscribed and applications will be scaled back.
- Shareholder allocations will be finalized in accordance with the terms of the SPP.
- Refunds for unsuccessful or scaled-back applications will be processed promptly.
- New shares are expected to be issued and commence trading soon after the allocation date.
- The company thanked shareholders for their support and participation.
- Contact details for further inquiries were provided in the announcement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Astron Corporation Limited (ATR) ORDINARY FULLY PAID |
Materials |
$241 |
Updated Donald Project Economics - Phase 1
|
23 Jul 2025 8:34AM |
$0.785 |
$0.560 |
fallen by
28.66%
|
|
ATR - Price-sensitive ASX Announcement
Full Release
Key Points
- Astron Corporation Limited released an updated economic assessment for Phase 1 of the Donald Rare Earth and Mineral Sands Project.
- The project is located in Victoria, Australia, and contains significant reserves of rare earth elements and mineral sands.
- Key improvements include increased project NPV and IRR, along with a reduction in the payback period.
- Updates are based on revised capital and operating costs, updated product pricing, and changes to the mining schedule.
- The revised assessment reflects market outlook and cost assumptions as of June 2023.
- The report highlights the strategic importance of the Donald Project for global supply of critical minerals.
- Astron aims to advance the project to meet growing demand for rare earths and minerals essential to advanced technologies and clean energy industries.
- The company is continuing to optimize and de-risk the project as it proceeds towards development and financing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$213 |
Presentation to Noosa Mining Conference
|
23 Jul 2025 8:34AM |
$0.710 |
$0.790 |
risen by
11.27%
|
|
| QPM Energy Limited (QPM) ORDINARY FULLY PAID |
Materials |
$71 |
TPS Update
|
23 Jul 2025 8:32AM |
$0.037 |
$0.018 |
fallen by
51.35%
|
|
| Atturra Limited (ATA) ORDINARY FULLY PAID |
Information Technology |
$155 |
Update - Notification of buy-back - ATA
|
23 Jul 2025 8:32AM |
$0.850 |
$0.420 |
fallen by
50.59%
|
|
| Great Boulder Resources Limited (GBR) ORDINARY FULLY PAID |
Materials |
$121 |
Noosa Mining Conference presentation
|
23 Jul 2025 8:31AM |
$0.063 |
$0.077 |
risen by
22.22%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$110 |
NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
|
23 Jul 2025 8:30AM |
$0.350 |
$0.450 |
risen by
28.57%
|
|
NYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Nyrada Inc advances Xolatryp Phase IIa clinical trial in cardioprotection.
- The trial focuses on reducing cardiac damage during procedures that can cause myocardial injury.
- Xolatryp is a novel, first-in-class therapeutic candidate developed by Nyrada Inc.
- Previous preclinical and Phase I studies have been successfully completed.
- The company has secured regulatory approvals to commence the Phase IIa trial.
- Patient recruitment for the trial has begun.
- Xolatryp addresses an unmet need in cardiovascular medicine, specifically for cardioprotection.
- The trial will assess safety, pharmacokinetics, and preliminary efficacy endpoints.
- Nyrada Inc aims to reduce the global burden of cardiovascular disease through novel treatments.
- Xolatryp may represent a breakthrough in protecting heart tissue from ischemic damage.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$7,862 |
Growing Fuel and Convenience Earnings
|
23 Jul 2025 8:30AM |
$26.890 |
$32.990 |
risen by
22.69%
|
|
ALD - Price-sensitive ASX Announcement
Full Release
Key Points
- Ampol Limited (ASX:ALD) reported a Group Replacement Cost Operating Profit (RCOP) EBITDA of ~$640 million for the first half of the 2025 financial year.
- Convenience Retail segment showed growth in EBIT, driven by a favorable mix of premium fuels.
- New Zealand segment achieved modestly higher EBIT due to diversified market channels.
- Fuels & Infrastructure (F&I) Australia EBIT was similar to the previous year, with supply chain impacts mitigated by better margins in middle distillates.
- F&I International operations remained at breakeven, focusing on supply within the Ampol system.
- Lytton refinery's EBIT was around breakeven, supported by improved Lytton Refiner Margin.
- Ampol's interest expense and effective tax rate are expected to remain favorable.
- Further audited financial results will be released on 18 August 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$7,862 |
Growing Fuel and Convenience Earnings
|
23 Jul 2025 8:30AM |
$26.890 |
$32.990 |
risen by
22.69%
|
|
ALD - Price-sensitive ASX Announcement
Full Release
Key Points
- Ampol Limited reported a Group RCOP EBITDA of ~$640 million and RCOP EBIT of ~$400 million for the first half of 2025.
- Convenience Retail continued its trend of growing earnings, driven by a favorable mix of premium fuels.
- New Zealand segment achieved modest EBIT growth, benefiting from diversified market channels.
- Fuels & Infrastructure (F&I) Australia maintained EBIT levels comparable to the previous year.
- Lytton refinery's EBIT was around breakeven in the first half of 2025, supported by an improved Lytton Refiner Margin.
- The interest expense for 1H 2025 is expected to be in line with the prior period.
- Convenience Retail’s U-GO expanded to 34 sites in Australia.
- Overall Group sales volume decreased by 6.1% year-on-year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$467 |
June 2025 Quarterly Activity Report and Appendix 4C
|
23 Jul 2025 8:28AM |
$1.140 |
$2.380 |
risen by
108.77%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Report covers the quarter ending June 2025 for Race Oncology Ltd.
- Highlights significant clinical and preclinical progress, especially with bisantrene.
- Details updates on ongoing and planned clinical trials.
- Mentions collaborations with international research institutions.
- Provides regulatory and intellectual property developments.
- Appendix 4C includes a summary of cash receipts, expenditures, and end-of-quarter cash balance.
- Company maintains a strong focus on advancing its lead drug candidate.
- Operational activities are aligned with research and development goals.
- Financial position detailed in Appendix 4C supports ongoing business activities and research programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scentre Group (SCG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$20,004 |
DXS:DWSF Westfield Chermside investment and DXS transactions
|
23 Jul 2025 8:27AM |
$3.730 |
$3.830 |
risen by
2.68%
|
|
| Dexus (DXS) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$6,135 |
DWSF Westfield Chermside investment and DXS transactions
|
23 Jul 2025 8:27AM |
$7.050 |
$5.720 |
fallen by
18.87%
|
|
| Westpac Banking Corporation (WBC) ORDINARY FULLY PAID |
Financials |
$121,352 |
Update - Notification of buy-back - WBC
|
23 Jul 2025 8:27AM |
$32.650 |
$35.480 |
risen by
8.67%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$18 |
Completion of Recruitment in TRIPP-FFX Clinical Trial
|
23 Jul 2025 8:27AM |
$1.185 |
$0.590 |
fallen by
50.21%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited has completed recruitment for the TRIPP-FFX clinical trial.
- The TRIPP-FFX trial investigates the OncoSil™ device in combination with FOLFIRINOX for locally advanced pancreatic cancer.
- A total of 71 patients have been enrolled in the study.
- Clinical sites for the trial are located internationally.
- Completion of recruitment marks a major milestone in the company’s clinical program.
- The next steps involve data analysis and preparation for regulatory and commercial processes.
- The OncoSil™ device is designed to deliver targeted radiation directly to pancreatic tumors.
- The company acknowledges the contribution of patients, investigators, and clinical teams.
- Further updates will be provided as trial data becomes available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sovereign Metals Limited (SVM) ORDINARY FULLY PAID |
Materials |
$371 |
DFS Progressing Well with Completion of Geotechnical Program
|
23 Jul 2025 8:26AM |
$0.760 |
$0.565 |
fallen by
25.66%
|
|
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,734 |
Q4, FY25 Webcast Presentation
|
23 Jul 2025 8:25AM |
$2.860 |
$5.010 |
risen by
75.17%
|
|
Call 1300 880 160
Start a chat
Schedule a call
